Realm Therapeutics Plc (RLM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Realm Therapeutics Plc (RLM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8256
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Realm Therapeutics Plc (Realm Therapeutics), formerly PuriCore Plc is a biopharmaceutical company that develops small molecule therapies for diseases. The company uses its immunomodulatory technology for treating inflammatory diseases in dermatology, ophthalmology, and other diseases. Its pipeline portfolio includes drugs for the treatment of bacteria caused atopic dermatitis and airborne allergens caused allergic conjunctivitis in phase II stage; acne, psoriasis, and dry eye in preclinical stage. Realm Therapeutics offers topical solutions for itching, inflammation, cleansing, erythema, debriding and moisturizing chronic and acute wounds. The company operates through its subsidiary in the US. Realm Therapeutics is headquartered in London, the UK.

Realm Therapeutics Plc (RLM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Realm Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Realm Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
PuriCore Enters Into Co-Marketing Agreement With Onset Dermatologics 12
Equity Offering 13
Realm Therapeutics Files Registration Statement for Public Offering of ADS 13
Realm Therapeutics Raises USD26 Million in Private Placement of Shares 14
Realm Therapeutics Plc – Key Competitors 16
Realm Therapeutics Plc – Key Employees 17
Realm Therapeutics Plc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
May 02, 2018: Realm Therapeutics Announces Final Results for the Year Ended December 31, 2017 and Business Update 19
Sep 22, 2017: Realm Therapeutics: Interim Financial Results 21
Mar 22, 2017: Realm Therapeutics – Final Results and Business Update 22
Corporate Communications 25
May 02, 2018: Realm Therapeutics Files Registration for Nasdaq Listing of ADS 25
Nov 17, 2017: Realm Therapeutics Appoints Sandy Zweifach as Non-Executive Director & Non-Executive Directors Matthew Hammond and Daniel Hegglin Retire from the Board 26
Product News 27
07/06/2017: Realm Therapeutics – Presentation at World Congress on Inflammation 27
06/14/2017: Realm Therapeutics to present on PR013 at the 2017 Marcum Microcap Conference 28
Product Approvals 29
Mar 12, 2018: Realm Therapeutics Provides Update on RLM023 29
Aug 02, 2017: Realm Therapeutics Submits Investigational New Drug Application for PR013 for Allergic Conjunctivitis 30
Jan 30, 2017: Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitis 31
Clinical Trials 32
Oct 16, 2017: Realm Therapeutics to Present Update on Drug Development Program PR013 at 2017 BIO Investor Forum 32
Oct 16, 2017: Realm Therapeutics to Review Drug Development Program PR022 at 2017 BIO Investor Forum 33
Sep 21, 2017: Realm Therapeutics Provides Clinical Development Update on PR013 34
Sep 21, 2017: Realm Therapeutics Provides Clinical Development Update on PR022 35
Sep 11, 2017: Realm Therapeutics – FDA Permits PR013 to Proceed to Phase II Trial 36
Sep 07, 2017: Realm Therapeutics provides update on PR022 37
Sep 07, 2017: Realm Therapeutics to present update on PR013 at the Rodman & Renshaw 19th Annual Global Investment Conference 38
Jun 14, 2017: Realm Therapeutics to present on PR022 at the 2017 Marcum Microcap Conference 39
Feb 28, 2017: FDA Permits Realm Therapeutics to Proceed to Phase II Clinical Trial with PR022 for Atopic Dermatitis 40
Jan 05, 2017: Realm Therapeutics to provide update on PR-022 at the 2017 Dermatology Summit and Biotech Showcase 41
Jan 05, 2017: Realm Therapeutics to provide update on PR013 at the 2017 Dermatology Summit and Biotech Showcase 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Realm Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Realm Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Realm Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
PuriCore Enters Into Co-Marketing Agreement With Onset Dermatologics 12
Realm Therapeutics Files Registration Statement for Public Offering of ADS 13
Realm Therapeutics Raises USD26 Million in Private Placement of Shares 14
Realm Therapeutics Plc, Key Competitors 16
Realm Therapeutics Plc, Key Employees 17
Realm Therapeutics Plc, Subsidiaries 18

List of Figures
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Realm Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Realm Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Realm Therapeutics Plc (RLM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genworth Financial, Inc.:企業のM&A・事業提携・投資動向
    Genworth Financial, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Genworth Financial, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Kazakhtelecom (KZTK):企業の財務・戦略的SWOT分析
    Kazakhtelecom (KZTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Alzheimer’s Drug Discovery Foundation-製薬・医療分野:企業M&A・提携分析
    Summary Alzheimer's Drug Discovery Foundation (ADDF), formerly Institute for the Study of Aging is a drug discovery foundation that offers funds for drug discovery and development research programs in the field of Alzheimer’s disease, related dementias and cognitive aging. The foundation offers serv …
  • Scholastic Corp (SCHL):企業の財務・戦略的SWOT分析
    Scholastic Corp (SCHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Centene Corp (CNC):製薬・医療:M&Aディール及び事業提携情報
    Summary Centene Corp (Centene) is a healthcare service provider that offers services to government sponsored healthcare programs with focus on under-insured and uninsured individuals. It provides health plans through Medicaid, Medicare and Health Insurance Marketplace contracts; and other health sol …
  • Intec Pharma ltd (NTEC):企業の財務・戦略的SWOT分析
    Summary Intec Pharma Ltd (Intec Pharma) is a biopharmaceutical company that offers delivery solutions for drugs. The company’s pipeline products include drug indications for Parkinson’s disease, insomnia and other diseases. Its proprietary gastro retentive formulation, offers a drug delivery solutio …
  • ValiRx Plc (VAL):企業の財務・戦略的SWOT分析
    Summary ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2, and NAV3 cancer screening test. ValiRx uses GeneICE technology, which enables silen …
  • Brioche Pasquier S.A.:企業の戦略・SWOT・財務分析
    Brioche Pasquier S.A. - Strategy, SWOT and Corporate Finance Report Summary Brioche Pasquier S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Minnkota Power Cooperative Inc:企業の戦略的SWOT分析
    Minnkota Power Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Sherritt International Corp (S):石油・ガス:M&Aディール及び事業提携情報
    Summary Sherritt International Corp (Sherritt) is a natural resources company. It carries out mining and refining activities for the production of nickel and cobalt from lateritic ores with ownership stake in Moa Joint Venture and Ambatovy Joint Venture. The company also explores, develops and produ …
  • Bukwang Pharmaceutical Co Ltd (003000):企業の財務・戦略的SWOT分析
    Summary Bukwang Pharmaceutical Co Ltd (Bukwang Pharmaceutical) is a pharmaceutical company that develops new drugs and pharmaceutical products. The company’s products portfolio includes dexide, chioctaside, levovir, orfil, lonacene, axima, and excel, among others. Its pipeline products comprise JM-0 …
  • Curemark LLC-医療機器分野:企業M&A・提携分析
    Summary Curemark LLC (Curemark) is a biopharmaceutical company that offers development of novel therapies. The company develops novel therapies to treat serious diseases for which there are limited treatment options. It provides CM-AT, CM-4612, CM-PK, CM-182, and CM-1212 drugs. Curemark’s product ca …
  • Orpak Systems Limited:企業の戦略的SWOT分析
    Orpak Systems Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Dolphin Drilling A.S.A. (FOE):企業の財務・戦略的SWOT分析
    Summary Dolphin Drilling ASA (Dolphin Drilling) is an oil and gas company that offers drilling contract and deep water services. The company's services include exploration and production services, repair services, fleet operations and management, pressure drilling, and deep water drilling services. …
  • Nabors Industries Ltd (NBR):石油・ガス:M&Aディール及び事業提携情報
    Summary Nabors Industries Ltd (Nabors) is an oil and gas contract services provider that offers offshore platform work over and drilling rigs. It also provides directional drilling services, performance tools and innovative drilling technologies and drilling instrumentation and software to the world …
  • Akers Biosciences Inc (AKER):医療機器:M&Aディール及び事業提携情報
    Summary Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. Its products include BreathScan alcohol detectors, CHUBE, METRO …
  • CropEnergies AG (CE2):企業の財務・戦略的SWOT分析
    CropEnergies AG (CE2) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Admiral Taverns Ltd.:企業の戦略・SWOT・財務情報
    Admiral Taverns Ltd. - Strategy, SWOT and Corporate Finance Report Summary Admiral Taverns Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Memorial Health System:企業の戦略的SWOT分析
    Memorial Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Escorts Ltd:企業の戦略・SWOT・財務情報
    Escorts Ltd - Strategy, SWOT and Corporate Finance Report Summary Escorts Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆